Evidence map›Paper›PMID 33649853›Full record

ArticleOncology reports2021

Lycorine inhibits cell proliferation, migration and invasion, and primarily exerts

Ping Zhang, Xiaohui Yuan, Tingting Yu, Huakun Huang, Chunmei Yang, Lulu Zhang, Shengdong Yang, Xiaoji Luo, Jinyong Luo

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Potential Antiviral Action of Alkaloids.Molecules (Basel, Switzerland) · 2022
    Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ping ZhangDepartment of Laboratory Medicine, Tianfu New Area People's Hospital, Chengdu, Sichuan 610213, P.R. China.
Xiaohui YuanKey Laboratory of Clinical Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China.
Tingting YuKey Laboratory of Clinical Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China.
Huakun HuangKey Laboratory of Clinical Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China.
Chunmei YangKey Laboratory of Clinical Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China.
Lulu ZhangKey Laboratory of Clinical Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China.
Shengdong YangDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Xiaoji LuoDepartment of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Jinyong LuoKey Laboratory of Clinical Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China.
Children's Hospital of Chongqing Medical University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNThe First People's Hospital of Tianmen · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a life‑threatening malignant tumor of the digestive tract. Diverse gene mutations and complicated alterations to the signaling pathways in CRC lead to heterogeneity in response to chemotherapy. Moreover, anticancer drugs for CRC chemotherapy are limited due to adverse events. Therefore, developing more effective, tolerable and safe drugs for the treatment of CRC is important. The present study aimed to investigate the effect of lycorine on human CRC cell proliferation, migration, invasion, apoptosis, cell cycle distribution, as well as the underlying molecular mechanism. The crystal violet staining and MTT assay results demonstrated that lycorine suppressed cell proliferation in a dose‑ and time‑dependent manner in the three CRC cell lines, HCT116, LoVo and SW480. Similarly, verified by performing wound healing and Transwell assays, lycorine significantly inhibited HCT116 and LoVo cell migration and invasion

Indexed as

Amaryllidaceae AlkaloidsAntineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsHCT116 CellsHumansMAP Kinase Signaling SystemNeoplasm Invasivenessp38 Mitogen-Activated Protein KinasesPhenanthridinesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesAmaryllidaceae AlkaloidsAntineoplastic Agentslycorinep38 Mitogen-Activated Protein KinasesPhenanthridinesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesAKTcolorectal cancer cellscytostasislycorineROS/p38

Identifiers

PMID33649853
PMCPMC7879421
OpenAlexW3128064198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.